Recent share performance and business snapshot

ACADIA Pharmaceuticals (ACAD) has been trading with mixed short term moves, with the stock up 0.6% over the past day and 4.5% over the past week, but down over the month and past 3 months.

The company is valued at about US$3.7b, with a last close of US$21.84. All of its US$1,095.25m in revenue comes from the United States through its focus on neurological and rare disease treatments.

Short term share price momentum for ACADIA has picked up, but this follows a year where the stock and total shareholder return are both down, hinting at shifting expectations around future growth and risk.

If ACADIA's recent swings have you thinking about where growth in healthcare could come from next, it may be worth scanning a curated list of 39 healthcare AI stocks as potential comparison ideas.

With ACADIA generating US$1,095.25m in revenue and US$375.65m in net income, yet trading below some valuation estimates, the key question is whether the current price signals undervaluation or if the market is already pricing in future growth.

Most Popular Narrative: 24% Undervalued

According to the most followed narrative, ACADIA's fair value of $28.75 sits meaningfully above the last close at $21.84, which frames the stock as undervalued based on that work.

ACADIA’s valuation reflects market caution. Investors are pricing in uncertainty around pipeline expansion and long-term growth durability. Yet that same caution creates optionality. Any evidence of sustained diversification or improved operating leverage could shift sentiment quickly.

Curious what underpins that gap between price and fair value? The narrative leans heavily on sustained revenue growth, expanding margins, and a maturing specialty pharma earnings profile. Want to see how those moving parts connect in detail?

Result: Fair Value of $28.75 (UNDERVALUED)

However, the story cuts both ways, with heavy reliance on US$1,095.25m of US based revenue and a concentrated neurological pipeline, leaving little room for execution missteps.

Next Steps

With mixed views around risk and reward emerging, it makes sense to look at the data yourself and decide where you stand. To weigh both sides in one place, start with the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If ACADIA has caught your attention, do not stop here. Broadening your watchlist with fresh ideas can help you compare risk, resilience, and income potential more clearly.

• Spot potential value opportunities early by scanning the 46 high quality undervalued stocks that match your preferred quality and pricing filters.
• Prioritize resilience first by checking companies in the 63 resilient stocks with low risk scores that align with your comfort level on volatility and balance sheet strength.
• Hunt for less crowded opportunities by reviewing the screener containing 21 high quality undiscovered gems before other investors start paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.